se ha leído el artículo
array:24 [ "pii" => "S0213911108760825" "issn" => "02139111" "doi" => "10.1016/S0213-9111(08)76082-5" "estado" => "S300" "fechaPublicacion" => "2008-04-01" "aid" => "76082" "copyright" => "Sociedad Española de Salud Pública y Administración Sanitaria" "copyrightAnyo" => "2008" "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Gac Sanit. 2008;22 Supl 1:111-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2086 "formatos" => array:3 [ "EPUB" => 151 "HTML" => 1493 "PDF" => 442 ] ] "itemSiguiente" => array:19 [ "pii" => "S0213911108760837" "issn" => "02139111" "doi" => "10.1016/S0213-9111(08)76083-7" "estado" => "S300" "fechaPublicacion" => "2008-04-01" "aid" => "76083" "copyright" => "Sociedad Española de Salud Pública y Administración Sanitaria" "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Gac Sanit. 2008;22 Supl 1:118-25" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2683 "formatos" => array:3 [ "EPUB" => 166 "HTML" => 1783 "PDF" => 734 ] ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Capítulo 3. Prioridades generales y prestaciones individuales</span>" "titulo" => "Gobernabilidad del Sistema Nacional de Salud: mejorando el balance entre los beneficios y los costes de la descentralización. Informe SESPAS 2008" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "118" "paginaFinal" => "125" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Governability of the Spanish national health system: improving the balance between the benefits and costs of decentralization" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "José R. Repullo, José M. Freire" "autores" => array:2 [ 0 => array:2 [ "nombre" => "José R." "apellidos" => "Repullo" ] 1 => array:2 [ "nombre" => "José M." "apellidos" => "Freire" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213911108760837?idApp=WGSE" "url" => "/02139111/00000022000000S1/v1_201301221349/S0213911108760837/v1_201301221349/es/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S0213911108760813" "issn" => "02139111" "doi" => "10.1016/S0213-9111(08)76081-3" "estado" => "S300" "fechaPublicacion" => "2008-04-01" "aid" => "76081" "copyright" => "Sociedad Española de Salud Pública y Administración Sanitaria" "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Gac Sanit. 2008;22 Supl 1:104-10" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2012 "formatos" => array:3 [ "EPUB" => 114 "HTML" => 1468 "PDF" => 430 ] ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Capítulo 2. Políticas de salud pública</span>" "titulo" => "Políticas de salud (actuaciones poblacionales) en los servicios asistenciales. Informe SESPAS 2008" "tienePdf" => "es" "tieneTextoCompleto" => 0 "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "104" "paginaFinal" => "110" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Health policies [population interventions] in health services" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Andreu Segura" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Andreu" "apellidos" => "Segura" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213911108760813?idApp=WGSE" "url" => "/02139111/00000022000000S1/v1_201301221349/S0213911108760813/v1_201301221349/es/main.assets" ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Capítulo 2. Políticas de salud pública</span>" "titulo" => "El impacto de los medicamentos en el bienestar. Informe SESPAS 2008" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "111" "paginaFinal" => "117" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Vicente Ortún" "autores" => array:1 [ 0 => array:4 [ "nombre" => "Vicente" "apellidos" => "Ortún" "email" => array:1 [ 0 => "vicente.ortun@upf.edu" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">¿</span>" "identificador" => "cor1" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:1 [ "entidad" => "Universitat Pompeu Fabra, Barcelona, España" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor1" "etiqueta" => "⁎" "correspondencia" => "Correspondencia: Vicente Ortún. Universitat Pompeu Fabra." ] ] ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "The impact of drugs on social welfare" ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:2 [ "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec13651" "palabras" => array:8 [ 0 => "Política farmacéutica" 1 => "Efectividad de los medicamentos" 2 => "Productividad" 3 => "Innovación" 4 => "Investigación y desarrollo" 5 => "Política industrial" 6 => "Regulación de precios" 7 => "España" ] ] ] "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Key words" "identificador" => "xpalclavsec13652" "palabras" => array:8 [ 0 => "Pharmaceutical policy" 1 => "Drug's effectiveness" 2 => "Productivity" 3 => "Innovation" 4 => "Research and development" 5 => "Industrial policy" 6 => "Price regulation" 7 => "Spain" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<p class="elsevierStyleSimplePara elsevierViewall">Se argumentan las razones de la intervención del Estado con relación a los medicamentos, y se destacan dos de sus perspectivas más habituales, la sanitaria y la industrial, perspectivas que en España tienden a ignorarse, entrar en conflicto o confundirse. Se revisa el creciente impacto de los medicamentos sobre el estado de salud y sobre la productividad que aporta una industria como la farmacéutica, intensiva en conocimiento.</p><p class="elsevierStyleSimplePara elsevierViewall">El impacto en el bienestar de los fármacos dependerá de cómo se gestione la prescripción en el marco de unas políticas macro manifiestamente mejorables. Se valoran tres grandes líneas de actuación y, en un texto preocupado por la efectividad de las políticas, se recomienda un mayor uso de la competencia en precios, señales regulatorias que premien a los medicamentos más innovadores (los que ofrezcan la mayor efectividad incremental en relación con el coste añadido respecto a las alternativas ya disponibles), una sacudida al sistema nacional de innovación y la imprescindible alineación de los incentivos de los prescriptores con los de un sistema sanitario que, cerrando sus brechas entre eficacia y efectividad, pueda ser cada vez más deseable y, por tanto, sostenible.</p>" ] "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<p class="elsevierStyleSimplePara elsevierViewall">The reasons and rationale for state intervention in the pharmaceutical industry are discussed with emphasis on two of the most frequent perspectives: the health-focused view and the income-centered approach; these perspectives tend to be ignored, to come into conflict, or to be confused in Spain. The growing impact of drugs on health and on the productivity of a knowledge-intensive industry – such as the pharmaceutical sector – is discussed.</p><p class="elsevierStyleSimplePara elsevierViewall">The impact of drugs on welfare will depend on how prescription is dealt with within the framework of some macro policies that could clearly be improved. The present article focuses on the effectiveness of Spanish pharmaceutical policy and assesses three families of policies. Several recommendations are made: greater use of price competition, regulatory signals rewarding the most innovative drugs (those that offer the greater incremental cost-effectiveness with respect to the already existing alternatives), a shake-up of the national system of innovation, and the indispensable alignment of prescriber incentives and the health system. An integrated pharmaceutical policy would help to bridge the quality chasm of the Spanish health system by making it more desirable, and therefore sustainable.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "Bibliografía" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:24 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Nordhaus W. The health of nations: the contribution of improved health to living standards. Cambridge: National Bureau of Economic Research; 2002. NBER Working Paper 8818." ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Alternativas a la distribución de medicamentos y su retribución" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "R. Meneu" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Gac Sanit" "fecha" => "2002" "volumen" => "16" "paginaInicial" => "171" "paginaFinal" => "181" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11958754" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Gestión de los medicamentos en los sistemas de salud. La perspectiva de la microgestión" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "J.L. Segú" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:4 [ "titulo" => "Elementos para la gestión de la prescripción y prestación farmacéuticas" "paginaInicial" => "173" "paginaFinal" => "221" "serieFecha" => "2004" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The role of public health improvements in health advances: the 20th century United States" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "D. Cutler" 1 => "G. Miller" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Demography" "fecha" => "2005" "volumen" => "42" "paginaInicial" => "1" "paginaFinal" => "22" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15782893" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:1 [ "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:2 [ "titulo" => "Innovaciones en gestión clínica y sanitaria" "serieFecha" => "2005" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Your money or your life" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "D. Cutler" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:3 [ "fecha" => "2004" "editorial" => "Oxford University Press" "editorialLocalizacion" => "Oxford" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Eficiencia y despilfarro en la atención sanitaria. A propósito del infarto de miocardio" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "R. Meneu" 1 => "S. Peiró" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Cuadernos Económicos de ICE" "fecha" => "2004" "volumen" => "67" "paginaInicial" => "9" "paginaFinal" => "25" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "López-Valcárcel BG, Pinilla J. The impact of medical technology on health: a longitudinal analysis of ischemic heart disease. Value in Health. 2008;11:88-96. Disponible en: <a class="elsevierStyleInterRef" href="http://www.blackwell-synergy.com/toc/vhe/0/0">http://www.blackwell-synergy.com/toc/vhe/0/0</a>" ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Productividad marginal del gasto e innovaciones sanitarias. Resultados empíricos y lecciones para España" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J. Puig-Junoy" 1 => "A. Merino" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:4 [ "titulo" => "¿Más recursos para la salud?" "paginaInicial" => "133" "paginaFinal" => "154" "serieFecha" => "2004" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Are the benefits of newer drugs worth their cost?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "F. Lichtenberg" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Health Affairs" "fecha" => "2001" "volumen" => "20" "paginaInicial" => "241" "paginaFinal" => "251" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11558710" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Lichtenberg F. Benefits and costs of newer drugs. An update. Cambridge: National Bureau of Economic Research; 2002. NBER Working Paper 8996." ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Do newer prescription drugs pay for themselves? A reassessment of the evidence" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "Y. Zhang" 1 => "S. Soumerai" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1377/hlthaff.26.3.880" "Revista" => array:6 [ "tituloSerie" => "Health Affairs" "fecha" => "2007" "volumen" => "26" "paginaInicial" => "880" "paginaFinal" => "886" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17485770" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The impact of new drugs on US longevity and medical expenditures, 1990-2003: evidence from longitudinal, disease level-data" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "F. Lichtenberg" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Am Econ Rev" "fecha" => "2007" "volumen" => "97" "paginaInicial" => "438" "paginaFinal" => "443" ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Monitoring industrial research: industrial R&D economic and policy analysis report 2006" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "A. Brandsma" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:3 [ "fecha" => "2007" "editorial" => "Office for Offical Publications of the European Communities" "editorialLocalizacion" => "Luxemburgo" ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "La financiación y regulación del precio de los medicamentos en el Sistema Nacional de Salud: cambios y continuidad" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "J. Puig-Junoy" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Gac Sanit" "fecha" => "2007" "volumen" => "21" "paginaInicial" => "1" "paginaFinal" => "4" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17306178" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "OECD Economic Survey Spain" "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "OCDE" "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Libro" => array:3 [ "fecha" => "2007" "editorial" => "OCDE" "editorialLocalizacion" => "París" ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib17" "etiqueta" => "17." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Ortún V. Desempeño y deseabilidad del sistema sanitario. Revista Asturiana de Economía. 2006;35:23-43. Disponible en: <a class="elsevierStyleInterRef" href="http://www.revistaasturianadeeconomia.org/raepdf/35/P23ORT%20UN.pdf">http://www.revistaasturianadeeconomia.org/raepdf/35/P23ORT UN.pdf</a>" ] ] ] 17 => array:3 [ "identificador" => "bib18" "etiqueta" => "18." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Office of Fair Trading. The Pharmaceutical Price Regulation Scheme. London: Office of Fair Trading; 2007. Disponible en: <a class="elsevierStyleInterRef" href="http://www.oft.gov.uk/advice_and_resources/resource_base/market-studies/price-regulation">http://www.oft.gov.uk/advice_and_resources/resource_base/market-studies/price-regulation</a>" ] ] ] 18 => array:3 [ "identificador" => "bib19" "etiqueta" => "19." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Patentes, regulación de precios e innovación en la industria farmacéutica" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "V. Ortún" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Cuadernos Económicos de ICE" "fecha" => "2004" "volumen" => "67" "paginaInicial" => "191" "paginaFinal" => "207" ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib20" "etiqueta" => "20." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Cabrales A, Jiménez-Martín S. The determinants of pricing of pharmaceuticals. Are US prices really higher than those of Canada. Barcelona: Departamento de Economía y Empresa; 2007. Working paper 1032. Disponible en: <a class="elsevierStyleInterRef" href="http://www.econ.upf.edu/docs/papers/downloads/1032.pdf">http://www.econ.upf.edu/docs/papers/downloads/1032.pdf</a>" ] ] ] 20 => array:3 [ "identificador" => "bib21" "etiqueta" => "21." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Incentivos a prescriptores" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "L. Cabiedes" 1 => "V. Ortún" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "LibroEditado" => array:4 [ "titulo" => "Análisis económico de la financiación pública de medicamentos" "paginaInicial" => "143" "paginaFinal" => "160" "serieFecha" => "2002" ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib22" "etiqueta" => "22." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Accuracy of pharmaceutical advertisements in medical journals" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "P. Villanueva" 1 => "S. Peiró" 2 => "J. Librero" 3 => "I. Pereiró" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(06)67917-8" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2003" "volumen" => "367" "paginaInicial" => "27" "paginaFinal" => "32" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16399148" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib23" "etiqueta" => "23." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "La ética en la relación con la industria farmacéutica Encuesta de opinión a los médicos de familia en Cataluña" "autores" => array:1 [ 0 => array:2 [ "colaboracion" => "Grupo de Ética Sociedad Catalana Medicina Familiar y Comunitaria" "etal" => false ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Aten Primaria" "fecha" => "2004" "volumen" => "34" "paginaInicial" => "6" "paginaFinal" => "12" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15207192" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib24" "etiqueta" => "24." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "La promoción farmacéutica, entre la confusión y la tergiversación. A propósito de la promoción de la doxazosina en el tratamiento combinado de la hipertensión" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "P. Cervera" 1 => "V. Ruiz" 2 => "S. Peiró" 3 => "V. Gosalbes" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Farmacia de Atención Primaria" "fecha" => "2004" "volumen" => "2" "paginaInicial" => "40" "paginaFinal" => "46" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "es" "url" => "/02139111/00000022000000S1/v1_201301221349/S0213911108760825/v1_201301221349/es/main.assets" "Apartado" => array:4 [ "identificador" => "716" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Capítulo 2. Políticas de salud pública" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/02139111/00000022000000S1/v1_201301221349/S0213911108760825/v1_201301221349/es/main.pdf?idApp=WGSE&text.app=https://gacetasanitaria.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213911108760825?idApp=WGSE" ]
año/Mes | Html | Total | |
---|---|---|---|
2024 Noviembre | 6 | 2 | 8 |
2024 Octubre | 57 | 34 | 91 |
2024 Septiembre | 54 | 27 | 81 |
2024 Agosto | 63 | 32 | 95 |
2024 Julio | 40 | 25 | 65 |
2024 Junio | 41 | 24 | 65 |
2024 Mayo | 45 | 32 | 77 |
2024 Abril | 37 | 24 | 61 |
2024 Marzo | 49 | 29 | 78 |
2024 Febrero | 33 | 38 | 71 |
2024 Enero | 30 | 18 | 48 |
2023 Diciembre | 34 | 21 | 55 |
2023 Noviembre | 42 | 36 | 78 |
2023 Octubre | 29 | 22 | 51 |
2023 Septiembre | 40 | 23 | 63 |
2023 Agosto | 35 | 16 | 51 |
2023 Julio | 37 | 21 | 58 |
2023 Junio | 41 | 14 | 55 |
2023 Mayo | 18 | 9 | 27 |